Robert Ford: Sure. Yes, there’s visibility. I mean, the visibility is in the first half of 2024, then I’d say no, but we do have a plan to be able to kind of drive gross margin and gross margin expansion. I’d say as you look at it into next year, Jayson, there’s really a couple of elements here that will be tailwinds for us. I’d say lower commodity costs, that for sure. And those were pretty big headwinds for us in, I’d say, in 2022 and 2023. On one hand, you’ve got commodity costs in nutrition, but you also got other commodity costs that are impacting the entire company. And what we have seen, and I think a lot of companies have seen is, those commodity costs start to bend and move down the other way. So — and that will be particularly important for us as we think about nutrition, which is highly dependent on a large number of commodity and commodity inputs.
Seeing a lower freight and distribution. And again, I think a lot of companies are seeing that, but we’re seeing that not only just in terms of rates, but also with more normalized supply chains, we can use different modalities of freight that can also lower cost and not using air all the time. So that’s going to help. We’ve got a, I think, a pretty robust process and teams in place that work on gross margin and gross margin improvement plans, they have been very busy, I’d say, over the last 12 months, 18 months. I expect those teams to continue to deliver on their strategies to deliver cost reductions, and then favorable product and portfolio mix, right? So as our faster-growing, higher-margin businesses and new products become a large portion of our overall sales and sales mix.
I think that also contributes to that. So yes, we understand that gross margin is key to be able to deliver on that double-digit bottom line EPS growth. And we’re — this is something that we work on every year. And I think we’ve got a little bit more of a better environment for our teams to work on. So — on your COVID question, I’ll ask Phil to give you the details there.
Philip Boudreau: Jason, relative to 2023 COVID testing sales forecast full year is about $1.5 billion here.
Robert Ford: Okay. So I’ll just wrap up here with a few comments. It’s clear that we’re seeing broad-based growth across the entire company. As I said in my comments, we’ve now delivered double-digit organic sales growth here for the past three quarters and forecasting that type of growth again this next quarter EPS contributions and the growth in the base business has increased every quarter, and we’ve exceeded the expectations we set for the initial guidance of the year. The pipeline to some of the points that were made there, a big kind of opportunity for us going into 2024 is our pipeline, and it continues to be productive with several new product approvals, indications reimbursement and geographic expansions there. So momentum is clearly building and well positioned for a strong end of the year and going into 2024. So with that, I’ll wrap up and thank you for joining us.
Mike Comilla: Thank you, operator, and thank you all for your questions. This now concludes Abbott’s conference call. A webcast replay of this call will be available after 11:00 a.m. Central Time today on Abbott’s Investor Relations website at abbottinvestor.com. Thank you for joining us today.
Operator: Thank you. This concludes today’s conference call. Thank you for your participation. You may now disconnect. Everyone, have a wonderful day.
